GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Forward PE Ratio

Longevity Biomedical (Longevity Biomedical) Forward PE Ratio : 0.00 (As of May. 17, 2024)


View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Forward PE Ratio?

Longevity Biomedical's Forward PE Ratio for today is 0.00.

Longevity Biomedical's PE Ratio without NRI for today is 0.00.

Longevity Biomedical's PE Ratio for today is 0.00.


Longevity Biomedical Forward PE Ratio Historical Data

The historical data trend for Longevity Biomedical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Forward PE Ratio Chart

Longevity Biomedical Annual Data
Trend
Forward PE Ratio

Longevity Biomedical Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Longevity Biomedical's Forward PE Ratio

For the Biotechnology subindustry, Longevity Biomedical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Biomedical's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Forward PE Ratio falls into.



Longevity Biomedical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Longevity Biomedical  (NAS:LBIO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Longevity Biomedical Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Biomedical (Longevity Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines